Adhoc: IGEA Pharma N.V.: IGEA Pharma has signed a preliminary agreement with LMH for a Euro 6.000.000 commitment to fund the completion of its Swiss CBD extraction facility

IGEA Pharma N.V. / Key word(s): Agreement/Agreement
IGEA Pharma N.V.: IGEA PHARMA HAS SIGNED A PRELIMINARY AGREEMENT WITH LMH-AN INDUSTRIAL HOLDING COMPANY-FOR A EURO 6.000.000 COMMITTMENT TO FUND THE COMPLETION OF ITS SWISS CBD EXTRACTION FACILITY

08-Jun-2022 / 00:14 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

---

IGEA PHARMA HAS SIGNED A PRELIMINARY AGREEMENT WITH LMH-AN INDUSTRIAL HOLDING COMPANY-FOR A EURO 6.000.000 COMMITTMENT TO FUND THE COMPLETION OF ITS SWISS CBD EXTRACTION FACILITY.

Hoofddorp, the Netherlands, 8^th June 2022. Today IGEA Pharma N.V. (SIX: IGPH) has signed a preliminary agreement with LMH Spa for a Euro 6.000.000 commitment to fund the completion of its GMP-Pharma CBD extraction facility owned through its joint-venture Blue Sky Swisse S.A.
The commitment will become unconditional after a customary due diligence and the signing of an agreement which will include, inter alia, the terms and conditions of the investment.
With the new funding IGEA Pharma forecasts that the joint venture will start production by Q2 2023 and expects a turnover of approximately Euro 30.0 million with an expected EBITDA margin of approximately 32.0%in 2023.
LMH Spa is characterized by an entrepreneurial approach to investments and will become a significant shareholder of IGEA Pharma to support the Company in its ambitious growth plan for the future.
The transaction is expected to close by June 30^th, 2022.

Vincenzo Moccia CEO said: "In the last few months IGEA has been focused on securing funding for the successful development of its CO2 supercritical extraction plant. After the completion of the business combination with Blue Sky Natural Resources Ltd, the Company is now ready to enter the next phase thanks to LMH - a holding specialized in the industrial development in the Food&Beverage, Healthcare and Fashion&Design sectors".

Francesco Marangon Head of Private Equity of LMH said: "We have been positively impressed by the scientific knowledge base behind the industrial plan and the overall quality of the management team of IGEA, and we are committed to support the Company in the long term by providing not only capital but valuable strategic advisory in order to reach a true global standing".

***

About IGEA
IGEA Pharma N.V. focuses through its Joint Venture on industrial CO2 supercritical extraction of CBD and other valuable components from their vegetable matrices for health prevention, pharma, food&beverage and other selected industries, with an innovative early-stage commercial and highly diversifiable pipeline.The company aims to become a center of excellence on highly controlled vegetable matrices and their industrial extraction technology. On the other hand, Igea operates on preventative health-tech products and devices, commercializing an Alzheimer's prevention set (which includes 'Alz1', an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded 'Alz1 Tab' designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in the next future. IGEA furthermore commercializes a COVID19 rapid test for the detection of IgM and IgG SARSCoV-2 related antibodies.

IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl

About LMH Holding
LMH SpA is a holding company headquartered in Padua, Italy operating in the Real Estate, Finance and Private Equity.It has been recently established as a boutique investment holding leveraging decades of business experience of a seasoned management team that has fully committed to the long-term vision of the founders.In the Private Equity sector, LMH is currently focused on building a solid portfolio of holdings,targeting future globalchampions that have untapped growth potentials, regardless of their fields of activity, from healthcare to fashion.
Find out more at www.lmh-holding.com

Contacts
Vincenzo Moccia, CEO, [phone], [e-mail]

Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA. The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development, or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward looking statements or to adapt them to future events or developments, except as may be required by law.

---

End of ad hoc announcement

---

Language:	English
Company:	IGEA Pharma N.V.
	Siriusdreef 17
	2123 WT Hoofddorp
	Netherlands
Phone:	[phone]
E-mail:	[e-mail]
Internet:	www.igeapharma.nl
ISIN:	NL0012768675
Listed:	Regulated Unofficial Market in Frankfurt; SIX Swiss Exchange
EQS News ID:	1370495

End of Announcement	EQS News Service

---

1370495 08-Jun-2022 CET/CEST